Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective

References

• ChenW, ZhengR, BaadePD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• SungH, RosenbergPS, ChenW-Q, et al. Female breast cancer incidence among Asian and Western populations: more similar than expected. JNCI. 2015;107(7):7. doi:10.1093/jnci/djv107
   Google Scholar
• ChengY, YanY, GongJ, YangN, NieS. Trends in incidence and mortality of female breast cancer during transition in Central China. Cancer Manage Res. 2018;10:6247–6255. doi:10.2147/CMAR.S182510
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Surveillance, Epidemiology and End Results Programme (SEER); 2020; Available from:https://seer.cancer.gov/. Accessed 101, 2020.
   Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: breast Cancer v4.2020; 2020. Available from:https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 101, 2020.
   Google Scholar
• TowleMJ, NomotoK, AsanoM, KishiY, YuMJ, LittlefieldBA. Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions. Anticancer Res. 2012;32(5):1611–1619.22593439
   PubMed Web of Science ®Google Scholar
• TowleMJ, SalvatoKA, BudrowJ, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 2001;61(3):1013–1021.11221827
   PubMed Web of Science ®Google Scholar
• KuznetsovG, TenDykeK, YuM, LittlefieldBA. Antiproliferative Effects of Halichondrin B Analog Eribulin Mesylate (E7389) Against Paclitaxel Resistant Human Cancer Cells in Vitro. Paper Presented At: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics. San Francisco; 2007.
   Google Scholar
• JordanMA, WilsonL. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4(4):253–265. doi:10.1038/nrc131715057285
   PubMed Web of Science ®Google Scholar
• TowleMJ, SalvatoKA, WelsBF, et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res. 2011;71(2):496–505. doi:10.1158/0008-5472.CAN-10-187421127197
   PubMed Web of Science ®Google Scholar
• JordanMA, KamathK, MannaT, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005;4(7):1086–1095. doi:10.1158/1535-7163.MCT-04-034516020666
   PubMed Web of Science ®Google Scholar
• AldayPH, CorreiaJJ. Macromolecular interaction of halichondrin B analogues eribulin (E7389) and ER-076349 with tubulin by analytical ultracentrifugation. Biochemistry. 2009;48(33):7927–7938. doi:10.1021/bi900776u19586046
   PubMed Web of Science ®Google Scholar
• SmithJA, WilsonL, AzarenkoO, et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry. 2010;49(6):1331–1337. doi:10.1021/bi901810u20030375
   PubMed Web of Science ®Google Scholar
• KuznetsovG, TowleMJ, ChengH, et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res. 2004;64(16):5760–5766. doi:10.1158/0008-5472.CAN-04-116915313917
   PubMed Web of Science ®Google Scholar
• AgoulnikS, KuznetsovG, TenDykeK, ParentLA, MarshJP, TwineN. Sensitivity to halichondrin analog E7389 and hemiasterlin analog E7974 correlates with βIII tubulin isotype expression in human breast cancer cell lines. J clin oncol. 2005;23(16_suppl):2012. doi:10.1200/jco.2005.23.16_suppl.201215774792
   PubMed Web of Science ®Google Scholar
• FunahashiY, OkamotoK, AdachiY, et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci. 2014;105(10):1334–1342. doi:10.1111/cas.1248825060424
   PubMed Web of Science ®Google Scholar
• CortesJ, O’ShaughnessyJ, LoeschD, et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914–923. doi:10.1016/S0140-6736(11)60070-621376385
   PubMed Web of Science ®Google Scholar
• KaufmanPA, AwadaA, TwelvesC, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J clin oncol. 2015;33(6):594–601. doi:10.1200/JCO.2013.52.489225605862
   PubMed Web of Science ®Google Scholar
• YuanP, HuX, SunT, et al. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: a randomised clinical trial. Eur j Cancer. 2019;112:57–65. doi:10.1016/j.ejca.2019.02.00230928806
   PubMed Web of Science ®Google Scholar
• WuY, WangQ, ZhangJ, CaoJ, WangB, HuX. Incidence of peripheral neuropathy associated with eribulin mesylate versus vinorelbine in patients with metastatic breast cancer: sub-group analysis of a randomized phase III study. Support Care Cancer. 2020;28(8):3819–3829. doi:10.1007/s00520-019-05112-531832821
   PubMed Web of Science ®Google Scholar
• TwelvesC, AwadaA, CortesJ, et al. Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer (Auckl). 2016;10:77–84. doi:10.4137/BCBCR.S3961527398025
   PubMed Web of Science ®Google Scholar
• TwelvesC, CortesJ, VahdatL, et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat. 2014;148(3):553–561. doi:10.1007/s10549-014-3144-y25381136
   PubMed Web of Science ®Google Scholar
• PivotX, MarmeF, KoenigsbergR, GuoM, BerrakE, WolferA. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Ann Oncol. 2016;27(8):1525–1531. doi:10.1093/annonc/mdw20327177860
   PubMed Web of Science ®Google Scholar
• CortesJ, TwelvesC. Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: a post hoc pooled analysis. Breast J. 2020;26(7):1347–1351. doi:10.1111/tbj.1368631782589
   PubMed Web of Science ®Google Scholar
• PivotX, ImSA, GuoM, MarmeF. Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer. 2018;25(3):370–374. doi:10.1007/s12282-017-0826-429302858
   PubMed Web of Science ®Google Scholar
• EisaiCLAnticancer agent halaven® approved for treatment of locally advanced or metastatic breast cancer in China. 2019; Available from:https://www.eisai.com/news/2019/news201952.html. Accessed 101, 2020.
   Google Scholar
• WatanabeJ, ItoY, OhsumiS, et al. Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study. Invest New Drugs. 2017;35(6):791–799. doi:10.1007/s10637-017-0486-428660549
   PubMed Web of Science ®Google Scholar
• JacotW, HeudelP-E, FraisseJ, et al. Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program. Int j Cancer. 2019;145(12):3359–3369. doi:10.1002/ijc.3240231087564
   PubMed Web of Science ®Google Scholar
• PouwelsX, GeurtsSME, RamaekersBLT, et al. The relative effectiveness of eribulin for advanced breast cancer treatment: a study of the southeast Netherlands advanced breast cancer registry. Acta Oncol. 2020;59(1):82–89. doi:10.1080/0284186X.2019.167035631583931
   PubMed Web of Science ®Google Scholar
• WilksS, PuhallaS, O’ShaughnessyJ, et al. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer. Clin Breast Cancer. 2014;14(6):405–412. doi:10.1016/j.clbc.2014.04.00425024001
   PubMed Web of Science ®Google Scholar
• O’ShaughnessyJ, McIntyreK, SchwartzbergL, et al. Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies. SpringerPlus. 2015;4(1):532. doi:10.1186/s40064-015-1322-y26413438
   PubMedGoogle Scholar
• PuhallaS, WilksS, BrufskyAM, et al. Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study. Breast Cancer. 2016;8:231–239. doi:10.2147/BCTT.S9869627994483
   PubMedGoogle Scholar
• SakaguchiK, NakatsukasaK, KoyamaH, et al. Phase II clinical trial of first-line eribulin plus trastuzumab for advanced or recurrent HER2-positive breast cancer. Anticancer Res. 2018;38(7):4073–4081. doi:10.21873/anticanres.1269729970533
   PubMed Web of Science ®Google Scholar
• InoueK, NinomiyaJ, SaitoT, et al. Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial. Invest New Drugs. 2019;37(3):538–547. doi:10.1007/s10637-019-00755-x30848403
   PubMed Web of Science ®Google Scholar
• YamashitaT, KawaguchiH, MasudaN, et al. Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2–positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study). Invest New Drugs. 2020. doi:10.1007/s10637-020-00991-6
   Web of Science ®Google Scholar
• YamashitaT, MasudaN, SajiS, et al. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD). Trials. 2020;21(1):391.32381018
   PubMed Web of Science ®Google Scholar
• AbrahamJ, RobidouxA, TanAR, et al. Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9. Breast Cancer Res Treat. 2015;152(2):399–405. doi:10.1007/s10549-015-3466-426126970
   PubMed Web of Science ®Google Scholar
• YardleyDA, ShipleyD, ZubkusJ, et al. A randomized phase ii study of eribulin/cyclophosphamide or docetaxel/cyclophosphamide as neoadjuvant therapy in operable HER2-negative breast cancer. Clin Breast Cancer. 2019;19(1):1–9. doi:10.1016/j.clbc.2018.08.00630245148
   PubMed Web of Science ®Google Scholar
• McIntyreK, O’ShaughnessyJ, SchwartzbergL, et al. Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer. Breast Cancer Res Treat. 2014;146(2):321–328. doi:10.1007/s10549-014-2923-924699910
   PubMed Web of Science ®Google Scholar
• OrtegaV, AntonA, GarauI, et al. Phase II, multicenter, single-arm trial of eribulin as first-line therapy for patients with aggressive taxane-pretreated HER2-negative metastatic breast cancer: the MERIBEL study. Clin Breast Cancer. 2019;19(2):105–112. doi:10.1016/j.clbc.2018.12.01230679100
   PubMed Web of Science ®Google Scholar
• TakashimaT, TokunagaS, TeiS, et al. A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer. SpringerPlus. 2016;5(1):164. doi:10.1186/s40064-016-1833-127026861
   PubMedGoogle Scholar
• KimuraK, IwamotoM, TanakaS, et al. A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes. Cancer Chemother Pharmacol. 2018;81(5):923–933. doi:10.1007/s00280-018-3567-y29594360
   PubMed Web of Science ®Google Scholar
• ParkYH, ImS-A, KimS-B, et al. Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. Eur j Cancer. 2017;86:385–393. doi:10.1016/j.ejca.2017.10.00229100193
   PubMed Web of Science ®Google Scholar
• TolaneySM, Barroso-SousaR, KeenanT, et al. Effect of eribulin with or without pembrolizumab on progression-free survival for patients with hormone receptor–positive, ERBB2 -negative metastatic breast cancer. JAMA Oncology. 2020;6(10):1598. doi:10.1001/jamaoncol.2020.352432880602
   PubMed Web of Science ®Google Scholar
• InoueK, TakahashiM, MukaiH, et al. Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting. Invest New Drugs. 2020;38(5):1540–1549. doi:10.1007/s10637-019-00890-531950374
   PubMed Web of Science ®Google Scholar
• PernasS, MartinM, KaufmanPA, et al. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. Lancet Oncol. 2018;19(6):812–824. doi:10.1016/S1470-2045(18)30147-529706375
   PubMed Web of Science ®Google Scholar
• LeeJS, YostSE, BlanchardS, et al. Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer. Breast Cancer Res. 2019;21(1):119. doi:10.1186/s13058-019-1202-431703728
   PubMed Web of Science ®Google Scholar
• YonemoriK, ShimomuraA, YasojimaH, et al. A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes. Eur j Cancer. 2019;109:84–91. doi:10.1016/j.ejca.2018.11.01430703739
   PubMed Web of Science ®Google Scholar
• KashiwagiS, AsanoY, GotoW, et al. Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer. PLoS One. 2017;12(2):e0170634. doi:10.1371/journal.pone.017063428166544
   PubMed Web of Science ®Google Scholar
• MiyagawaY, ArakiK, BunA, et al. Significant association between low baseline neutrophil-to-lymphocyte ratio and improved progression-free survival of patients with locally advanced or metastatic breast cancer treated with eribulin but not with nab-paclitaxel. Clin Breast Cancer. 2018;18(5):400–409. doi:10.1016/j.clbc.2018.03.00229605174
   PubMed Web of Science ®Google Scholar
• MiyoshiY, YoshimuraY, SaitoK, et al. High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician’s choice—in the EMBRACE study. Breast Cancer. 2020;27(4):706–715. doi:10.1007/s12282-020-01067-232133606
   PubMed Web of Science ®Google Scholar
• Chinese Anti-Cancer Association Breast Cancer Committee. Chinese Anti-Cancer Association breast cancer diagnosis and treatment guidelines [Chinese Language]. China Oncol. 2019;29(8).
   Google Scholar
• YanmeiL. Guidelines of Chinese Society of Clinical Oncology (CSCO): Breast Cancer. China; 2020.
   Google Scholar
• WozniakKM, WuY, FarahMH, LittlefieldBA, NomotoK, SlusherBS. Neuropathy-inducing effects of eribulin mesylate versus paclitaxel in mice with preexisting neuropathy. Neurotox Res. 2013;24(3):338–344. doi:10.1007/s12640-013-9394-323637052
   PubMed Web of Science ®Google Scholar
• WozniakKM, NomotoK, LapidusRG, et al. Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice. Cancer Res. 2011;71(11):3952–3962. doi:10.1158/0008-5472.CAN-10-418421498637
   PubMed Web of Science ®Google Scholar
• BenbowSJ, WozniakKM, KuleshB, et al. Microtubule-targeting agents eribulin and paclitaxel differentially affect neuronal cell bodies in chemotherapy-induced peripheral neuropathy. Neurotox Res. 2017;32(1):151–162. doi:10.1007/s12640-017-9729-628391556
   PubMed Web of Science ®Google Scholar
• VahdatLT, GarciaAA, VogelC, et al. Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy. Breast Cancer Res Treat. 2013;140(2):341–351. doi:10.1007/s10549-013-2574-223877339
   PubMed Web of Science ®Google Scholar
• ZuoT, ZengH, LiH, et al. The influence of stage at diagnosis and molecular subtype on breast cancer patient survival: a hospital-based multi-center study. Chin J Cancer. 2017;36(1):84. doi:10.1186/s40880-017-0250-329070080
   PubMedGoogle Scholar
• NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. NCCN Evidence Blocks. 2020; Available from:https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf. Accessed 101, 2020..
   Google Scholar
• National Comprehensive Cancer Network Evidence Blocks User Guide; 2020. Available from:https://www.nccn.org/evidenceblocks/pdf/EvidenceBlocksUserGuide.pdf. Accessed 101, 2020.
   Google Scholar
• SmithJ, IrwinA, JensenL, et al. Phase II study of eribulin mesylate administered biweekly in patients with human epidermal growth factor receptor-2–negative metastatic breast cancer. Clin Breast Cancer. 2020;20(2):160–167. doi:10.1016/j.clbc.2019.09.00731980406
   PubMed Web of Science ®Google Scholar
• Wikipedia. Avalablefrom: https://en.wikipedia.org/wiki/Eribulin.
   Google Scholar